Fig. 2From: Chromogranin-A production and fragmentation in patients with Takayasu arteritisLevels of CgA peptides and selected TA clinical features. Plasma concentrations of CgA439, CgA-FRs and VS-1 in the whole group of TA patients (left panels) and in those on PPI therapy (right panels), stratified for vascular enhancement (upper panels), disease activity (middle panels) and vascular progression (lower panels) (see “Methods”). CgA 439 full-length chromogranin-A (residues 1–439), CgA-FRs fragments of CgA spanning from the N-terminus to the central region but lacking the C-terminal region, PPI proton-pump inhibitors, VS-1 vasostatin-1Back to article page